Sponsor Pipeline

Sun Yat-sen University Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
178
Active Trials
83
Recruiting
33
Phase 3
10
Disease Areas
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-03 NCT07305064
A Virtual Peer Agent for Counseling Adolescents With Stressful Life Events
overall status: "Not Yet Recruiting" → "Completed"
2026-06-03 NCT07305064
A Virtual Peer Agent for Counseling Adolescents With Stressful Life Events
Enrollment increased: 50 -> 55 participants
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-06-10 NCT07638436 Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally… Phase 2 Recruiting
2026-06-09 NCT07635953 New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes Phase 3 Not Yet Recruiting
2026-06-09 NCT07636226 QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer Phase 2/3 Not Yet Recruiting
2026-06-05 NCT07630077 Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or… Phase 2 Not Yet Recruiting
2026-06-03 NCT07622771 Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally… Phase 2 Not Yet Recruiting
2026-06-03 NCT07622784 Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma Phase 2 Not Yet Recruiting
2026-06-02 NCT07621497 FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable… Phase 2 Not Yet Recruiting
2026-06-01 NCT07618624 BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent… Phase 2 Enrolling by Invitation
2026-05-29 NCT07615283 Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma Phase 1/2 Not Yet Recruiting
2026-05-28 NCT07610720 Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive… Phase 2 Recruiting
Active Trials by Phase
Phase 4
2
Phase 3
31
Phase 2/3
2
Phase 2
89
Phase 1/2
10
Phase 1
2
Early Phase 1
1
Not specified
41
Active Trials — top 25 of 178
NCT IDTitleConditionStatus
Phase 4
NCT06624696 Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at… Respiratory Hypersensitivity Recruiting
NCT06437288 Hematoporphyrin Photodynamic Therapy for Esophageal Cancer Esophageal Cancer Enrolling by Invitation
Phase 3
NCT06726421 Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney… Renal Cell Carcinoma (Kidney Cancer) Recruiting
NCT06239727 Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment… Nasopharyngeal Carcinoma Recruiting
NCT07125755 Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant… Squamous Cell Cancer of Head and Neck (SCCHN) Recruiting
NCT06545747 Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic… Non-small Cell Lung Cancer Recruiting
NCT07201337 Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in… Nasopharyngeal Cancinoma (NPC) Recruiting
NCT07481786 Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With… Lung Adenocarcinoma Recruiting
NCT07177794 Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC Esophageal Cancer Recruiting
NCT04944914 Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For… Nasopharyngeal Carcinoma Recruiting
NCT05357846 PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally… Squamous Cell Esophageal Carcinoma Recruiting
NCT07528209 Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally… Rectal Cancer Recruiting
NCT03907826 PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma… Recurrent Nasopharyngeal Carcinoma Recruiting
NCT07311772 Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral… Nasopharyngeal Cancinoma (NPC) Recruiting
NCT04436965 Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in… Nasopharyngeal Carcinoma Recruiting
NCT05340491 Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised… Nasopharyngeal Carcinoma Recruiting
NCT05941741 IC Plus Low-dose Radiation Plus Cadonilimab in LANPC Nasopharyngeal Carcinoma Recruiting
NCT03303495 A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC Colorectal Neoplasms Recruiting
NCT05198609 Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal… Hepatocellular Carcinoma Active, Not Recruiting
NCT07371897 Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial Head and Neck Squamous Cell Carcinoma HNSCC Not Yet Recruiting
NCT07373990 Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma Nasopharyngeal Cancinoma (NPC) Not Yet Recruiting
NCT07381660 SBRT Versus Surgical Resection for Small HCC Hepatocellular Carcinoma (HCC) Not Yet Recruiting
NCT07385079 Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma Nasopharyngeal Cancinoma (NPC) Not Yet Recruiting
NCT07402538 Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in… Oral Cancer Not Yet Recruiting
NCT07524413 Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk… Nasopharyngeal Cancinoma (NPC) Not Yet Recruiting
View all 178 active Sun Yat-sen University trials with filters →
Disease Areas
Get alerts when Sun Yat-sen University's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free